Molecular evidence for a clonal relationship between multiple lesions in patients with unknown primary adenocarcinoma

International Journal of Cancer

Volumn 123, Issue 6, 2008, Pages 1292-1300

  Speel, Ernst Jan M ^a,f   Van De Wouw, Agnes J ^b   Claessen, Sandra M H ^a   Haesevoets, Annick ^a   Hopman, Anton H N ^a   Van Der Wurff, Anneke A M ^c   Osieka, Rainhardt ^d   Buettner, Reinhard ^e   Hillen, Harry F P ^f   Ramaekers, Frans C S ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b VIECURI MEDICAL CENTER   (Netherlands)

^c Afd Pathologie   (Netherlands)

^d RWTH AACHEN UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL BONN   (Germany)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adenocarcinoma; Cancer of unknown primary origin; Clonal analysis; Comparative genomic hybridization; Immunohistochemistry; Microsatellite analysis; Unknown primary tumor

Indexed keywords

ADULT; AGED; ALLELE; ARTICLE; AUTOPSY; CANCER GROWTH; CANCER LOCALIZATION; CANCER OF UNKNOWN PRIMARY SITE; CANCER PATIENT; CHROMOSOMAL INSTABILITY; CLONE; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE FREQUENCY; GENE LOSS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR CLONING; MOLECULAR TYPING; MULTIPLE CANCER; PHENOTYPE; PRIORITY JOURNAL; TUMOR GROWTH; XENOGRAFT;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; CLONE CELLS; FEMALE; GENES, ERBB-2; GENES, P16; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, UNKNOWN PRIMARY;

EID: 49749110108     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23616     Document Type: Article

References (58)

1. Greco FA, Hainsworth JD. Cancer of unknown primary site. In: DeVita VT Jr, Hellman S, Rosenberg SA eds. Cancer principles and practice of oncology, 5th edn. Philadelphia (PA): Lippincott, 1995. 2072-92.
2. Hammar SP. Metastatic adenocarcinoma of unknown primary origin. Hum Pathol 1998;29:1393-1402.
3. Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer 2004;100:1776-85.
4. Van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, Hillen HF. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur J Cancer 2002;38:409-13.
5. Hillen HF. Unknown primary tumours. Postgrad Med J 2000;76: 690-3.
6. Motzer RJ, Rodriguez E, Reuter VE, Bosl GJ, Mazumdar M, Chaganti RS. Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site. J Clin Oncol 1995;13:274-82.
7. Ayoub JP, Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL. Unknown primary tumours metastatic to liver. J Clin Oncol 1998;16:2105-12.
8. Greco FA, Burris HA III, Litchy S, Barton JH, Bradof JE, Richards P, Scullin DC Jr, Erland JB, Morrissey LH, Hainsworth JD. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a minnie pearl cancer research network study. J Clin Oncol 2002;20:1651-6.
9. Califano J, Westra WH, Koch W, Meininger G, Reed A, Yip L, Boyle JO, Lonardo F, Sidransky D. Unknown primary head and neck squamous cell carcinoma: molecular identification of the site of origin. J Natl Cancer Inst 1999;91:599-604.
10. Kaufmann O, Fietze E, Dietel M. Immunohistochemical diagnosis in cancer metastasis of unknown primary tumour. Pathologe 2002; 23:183-97.
11. Pantou D, Tsarouha H, Papadopoulou A, Mahaira L, Kyriazoglou I, Apostolikas N, Markidou S, Trangas T, Pandis N, Bardi G. Cytogenetic profile of unknown primary tumours: clues for their pathogenesis and clinical management. Neoplasia 2003;5:23-31.
12. Van de Wouw AJ, Jansen RLH, Speel EJM, Hillen HFP. The unknown biology of the unknown primary tumour: a literature review. Annal Oncol 2003;14:191-6.
13. Nystrom JS, Weiner JM, Heffelfinger-Juttner J, Irwin LE, Bateman JR, Wolf RM. Metastatic and histologic presentations in unknown primary cancer. Semin Oncol 1977;4:53-8.
14. Le Chevalier T, Cvitkovic E, Caille P, Harvey J, Contesso G, Spielmann M, Rouesse J. Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. Arch Intern Med 1988;148:2035-9.
15. Gilbert HA, Kagan AR. Metastases: incidence, detection, and evaluation without histologic confirmation. In: Weiss L, ed. Fundamental aspects of metastasis. Amsterdam, the Netherlands: 1976;385-405.
16. Abbruzzese JL, Lenzi R, Raber MN, Pathak S, Frost P. The biology of unknown primary tumours. Semin Oncol 1993;20:238-43.
17. Riethmuller G, Klein CA. Early cancer cell dissemination and late metastatic relapse: clinical reflections and biological approaches to the dormancy problem in patients. Semin Cancer Biol 2001;11:307-11.
18. Hedley DW, Leary JA, Kirsten F. Metastatic adenocarcinoma of unknown primary site: abnormalities of cellular DNA content and survival. Eur J Cancer Clin Oncol 1985;21:185-9.
19. Bell CW, Pathak S, Frost P. Unknown primary tumours: establishment of cell lines, identification of chromosomal abnormalities, and implications for a second type of tumour progression. Cancer Res 1989;49:4311-15.
20. Bar-Eli M, Abbruzzese JL, Lee-Jackson D, Frost P. p53 gene mutation spectrum in human unknown primary tumours. Anticancer Res 1993;13:1619-23.
21. Gottschlich S, Schuhmacher O, Gorogh T, Hoffmann M, Maune S. Analysis of the p53 gene status of lymph node metastasis in the head and neck region in occult primary cancer. Laryngol Rhinol Otol 2000;79:434-7.
22. Hainsworth JD, Lennington WJ, Greco FA. Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site. J Clin Oncol 2000; 18:632-5.
23. Van de Wouw AJ, Jansen RLH, Griffioen AW, Hillen HFP. Clinical and immunohistochemical analysis of patients with unknown primary tumour. A search for prognostic factors in UPT. Anticancer Res 2004;24:297-302.
24. Garcia SB, Novelli M, Wright NA. The clonal origin and clonal evolution of epithelial tumours. Int J Exp Pathol 2000;81:89-116.
25. Markowitz SD, Dawson DM, Willis J, Willson JKV. Focus on colon cancer. Cancer Cell 2002;1:233-6.
26. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001;345:1890-900.
27. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
28. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
29. Van der Sijp JRM, Van Meerbeeck JPAM, Maat APWM, Zondervan PE, Sleddens HFBM, Van Geel AN, Eggermont AM, Dinjens WN. Determination of the molecular relationship between multiple tumours within one patient is of clinical importance. J Clin Oncol 2002;20:1105-14.
30. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992;258:818-21.
31. Solinas-Toldo S, Lampel S, Stilgenbauer S, Nickolenko J, Benner A, Döhner H, Cremer T, Lichter P. Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer 1997;20:399-407.
32. Begum S, Gillison ML, Ansari-Lari MA, Shah K, Westra WH. Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumour origin. Clin Cancer Res 2003;9:6469-75.
33. INK4a and p53 in the absence of mutations in p53 exons 5-8. Int J Cancer 2003;107:394-400.
34. Hopman AHN, Kamps MAF, Speel EJM, Schapers RF, Sauter G, Ramaekers FCS. Identification of chromosome 9 alterations and p53 accumulation in isolated carcinoma in situ of the urinary bladder versus carcinoma in situ associated with carcinoma. Am J Pathol 2002;161:1119-25.
35. Vousden KH, Prives C. p53 and prognosis: new insights and further complexity. Cell 2005;120:7-10.
36. Heider KH, Kuthan H, Stehle G, Munzert G. CD44v6: a target for antibody-based cancer therapy. Cancer Immunol Immunother 2004; 53:567-79.
37. Emens LA, Davidson NE. Trastuzumab in breast cancer. Oncology (Huntingt) 2004;18:1117-28.
38. Wessels PH, Twijnstra A, Kubat B, Ummelen MIJ, Claessen SMH, Sciot R, Merlo A, Ramaekers FCS, Speel EJM, Hopman AHN. 10q25.3 (DMBT1) copy number changes in astrocytoma grades II and IV. Genes Chromosomes Cancer 2004;39:22-8.
39. Friedrichs K, Franke F, Lisboa BW, Kugler G, Gille I, Terpe HJ, Hölzel F, Maass H, Günthert U. CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res 1995;55:5424-33.
40. Speel EJM, Richter J, Moch H, Egenter C, Saremaslani P, Rütimann K, Zhao J, Barghorn A, Roth J, Heitz PU, Komminoth P. Genetic differences in endocrine pancreatic tumour subtypes detected by comparative genomic hybridization. Am J Pathol 1999;155:1787-94.
41. Perren A, Roth J, Muletta-Feurer S, Saremaslani P, Speel EJM, Heitz PU, Komminoth P. Clonal analysis of sporadic pancreatic endocrine tumours. J Pathol 1998;186:363-71.
42. Mertens F, Johansson B, Mitelman F. Chromosomal imbalance maps of malignant solid tumours: a cytogenetic survey of 3185 neoplasms. Cancer Res 1997;57:2765-80.
43. Knuutila S, Aalto Y, Autio K, Björkqvist AM, El-Rifai W, Hemmer S, Huhta T, Kettunen E, Kiuru-Kuhlefelt S, Larramendy ML, Lushnikova T, Monni O, et al. DNA copy number losses in human neoplasms. Am J Pathol 1999;155:683-94.
44. Gebhart E, Liehr T. Patterns of genomic imbalances in human solid tumours. Int J Oncol 2000;16:383-99.
45. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-99.
46. Draviam VM, Xie S, Sorger PK. Chromosome segregation and genomic stability. Curr Opin Genet Dev 2004;14:120-5.
47. Naresh KN. Do metastatic tumours from an unknown primary reflect angiogenic incompetence of the tumour at the primary site? A hypothesis. Med Hypotheses 2002;59:357-60.
48. Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E, Kalofonos H, Fountzilas G, Fotsis T, Pavlidis N. Angiogenesis in cancer of unknown primary: clinicopathological study of CD34. VEGF and TSP-1. BMC Cancer 2005;5:25.
49. Pentheroudakis G, Briasoulis E, Pavlidis N. Cancer of unknown primary site: missing primary or missing biology? Oncologist 2007; 12:418-25.
50. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumours. Nat Genet 2003;33:49-54.
51. Van der Schaft DW, Seftor RE, Seftor EA, Hess AR, Gruman LM, Kirschmann DA, Yokoyama Y, Griffioen AW, Hendrix MJ. Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst 2004;96:1473-7.
52. Hermsen M, Postma C, Baak J, Weiss M, Rapallo A, Sciutto A, Roemen G, Arends JW, Williams R, Giaretti W, De Goeij A, Meijer G. Colorectal adenoma to carcinoma progression follows multiple pathways of chromosomal instability. Gastroenterology 2002;123:1109-19.
53. Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, Mooney J, Verbeke C, Bellamy C, Keith WN, Oien KA. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res 2005;11:3766-72.
54. Buckhaults P, Zhang Z, Chen Y-C, Wang T-L, St Croix B, Saha S, Bardelli A, Morin PJ, Polyak K, Hruban RH, Velculescu VE, Shih IeM. Identifying tumour origin using a gene expression-based classification map. Cancer Res 2003;63:4144-9.
55. Su AI, Welsh JB, Sapinoso LM, Kern SG, Dimitrov P, Lapp H, Schultz PG, Powell SM, Moskaluk CA, Frierson HF Jr, Hampton GM. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 2001;61:7388-93.
56. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson JA Jr, Marks JR, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-7.
57. Albertson DG, Pinkel D. Genomic microarrays in human genetic disease and cancer. Hum Mol Genet 2003;12:R145-R152.
58. Hillen HFP, Claessen SMH, Van Mierlo A, Haesevoets A, Hopman AHN, Ramaekers FCS, Van der Wurff AAM, Joosten S, Van de Wouw AJ, Speel EJM. Genetic analysis reveals evidence for a clonal relationship between multiple tumours in individual patients with unknown primary tumour. Proc ASCO 2002;21:453a (abstract 1810).